Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma

Junhee Park, Hyun Jeong Kim, Ki Rim Kim, Sun Kyoung Lee, Hyungkeun Kim, Kwang Kyun Park, WonYoon Chung

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

High recurrence and lower survival rates in patients with oral squamous cell carcinoma (OSCC) are associated with its bone invasion. We identified the oncogenic role of RUNX3 during bone invasion by OSCC. Tumor growth and the generation of osteolytic lesions were significantly inhibited in mice that were subcutaneously inoculated with RUNX3-knockdown human OSCC cells. RUNX3 knockdown enhanced TGF-β-induced growth arrest and inhibited OSCC cell migration and invasion in the absence or presence of transforming growth factor-β (TGF-β), a major growth factor abundant in the bone microenvironment. RUNX3 knockdown induced cell cycle arrest at the G1 and G2 phases and promoted G2 arrest by TGF-β in Ca9.22 OSCC cells. RUNX3 knockdown also inhibited both the basal and TGF-β-induced epithelial-tomesenchymal transition by increasing E-cadherin expression and suppressing the nuclear translocation of β-catenin. In addition, the expression and TGF-β-mediated induction of parathyroid hormone-related protein (PTHrP), one of key osteolytic factors, was blocked in RUNX3-knockdown OSCC cells. Furthermore, treating human osteoblastic cells with conditioned medium derived from RUNX3-knockdown OSCC cells reduced the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin ratio compared with treatment with conditioned medium from RUNX3-expressing cells. These findings indicate that RUNX3 expression in OSCC cells contributes to their bone invasion and the resulting osteolysis by inducing their malignant behaviors and production of osteolytic factors. RUNX3 alone or in combination with TGF-β and PTHrP may be a useful predictive biomarker and therapeutic target for bone invasion by oral cancer.

Original languageEnglish
Pages (from-to)9079-9092
Number of pages14
JournalOncotarget
Volume8
Issue number6
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Squamous Cell Carcinoma
Transforming Growth Factors
Bone and Bones
Parathyroid Hormone-Related Protein
Conditioned Culture Medium
RANK Ligand
Osteoprotegerin
Catenins
Osteolysis
G2 Phase
Mouth Neoplasms
G1 Phase
Cadherins
Growth
Cell Cycle Checkpoints
Growth Hormone
Cell Movement
Intercellular Signaling Peptides and Proteins
Survival Rate
Biomarkers

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Park, J., Kim, H. J., Kim, K. R., Lee, S. K., Kim, H., Park, K. K., & Chung, W. (2017). Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma. Oncotarget, 8(6), 9079-9092. https://doi.org/10.18632/oncotarget.14071
Park, Junhee ; Kim, Hyun Jeong ; Kim, Ki Rim ; Lee, Sun Kyoung ; Kim, Hyungkeun ; Park, Kwang Kyun ; Chung, WonYoon. / Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma. In: Oncotarget. 2017 ; Vol. 8, No. 6. pp. 9079-9092.
@article{01f084d336ff49c38db4980015784249,
title = "Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma",
abstract = "High recurrence and lower survival rates in patients with oral squamous cell carcinoma (OSCC) are associated with its bone invasion. We identified the oncogenic role of RUNX3 during bone invasion by OSCC. Tumor growth and the generation of osteolytic lesions were significantly inhibited in mice that were subcutaneously inoculated with RUNX3-knockdown human OSCC cells. RUNX3 knockdown enhanced TGF-β-induced growth arrest and inhibited OSCC cell migration and invasion in the absence or presence of transforming growth factor-β (TGF-β), a major growth factor abundant in the bone microenvironment. RUNX3 knockdown induced cell cycle arrest at the G1 and G2 phases and promoted G2 arrest by TGF-β in Ca9.22 OSCC cells. RUNX3 knockdown also inhibited both the basal and TGF-β-induced epithelial-tomesenchymal transition by increasing E-cadherin expression and suppressing the nuclear translocation of β-catenin. In addition, the expression and TGF-β-mediated induction of parathyroid hormone-related protein (PTHrP), one of key osteolytic factors, was blocked in RUNX3-knockdown OSCC cells. Furthermore, treating human osteoblastic cells with conditioned medium derived from RUNX3-knockdown OSCC cells reduced the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin ratio compared with treatment with conditioned medium from RUNX3-expressing cells. These findings indicate that RUNX3 expression in OSCC cells contributes to their bone invasion and the resulting osteolysis by inducing their malignant behaviors and production of osteolytic factors. RUNX3 alone or in combination with TGF-β and PTHrP may be a useful predictive biomarker and therapeutic target for bone invasion by oral cancer.",
author = "Junhee Park and Kim, {Hyun Jeong} and Kim, {Ki Rim} and Lee, {Sun Kyoung} and Hyungkeun Kim and Park, {Kwang Kyun} and WonYoon Chung",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.14071",
language = "English",
volume = "8",
pages = "9079--9092",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "6",

}

Park, J, Kim, HJ, Kim, KR, Lee, SK, Kim, H, Park, KK & Chung, W 2017, 'Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma', Oncotarget, vol. 8, no. 6, pp. 9079-9092. https://doi.org/10.18632/oncotarget.14071

Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma. / Park, Junhee; Kim, Hyun Jeong; Kim, Ki Rim; Lee, Sun Kyoung; Kim, Hyungkeun; Park, Kwang Kyun; Chung, WonYoon.

In: Oncotarget, Vol. 8, No. 6, 01.01.2017, p. 9079-9092.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma

AU - Park, Junhee

AU - Kim, Hyun Jeong

AU - Kim, Ki Rim

AU - Lee, Sun Kyoung

AU - Kim, Hyungkeun

AU - Park, Kwang Kyun

AU - Chung, WonYoon

PY - 2017/1/1

Y1 - 2017/1/1

N2 - High recurrence and lower survival rates in patients with oral squamous cell carcinoma (OSCC) are associated with its bone invasion. We identified the oncogenic role of RUNX3 during bone invasion by OSCC. Tumor growth and the generation of osteolytic lesions were significantly inhibited in mice that were subcutaneously inoculated with RUNX3-knockdown human OSCC cells. RUNX3 knockdown enhanced TGF-β-induced growth arrest and inhibited OSCC cell migration and invasion in the absence or presence of transforming growth factor-β (TGF-β), a major growth factor abundant in the bone microenvironment. RUNX3 knockdown induced cell cycle arrest at the G1 and G2 phases and promoted G2 arrest by TGF-β in Ca9.22 OSCC cells. RUNX3 knockdown also inhibited both the basal and TGF-β-induced epithelial-tomesenchymal transition by increasing E-cadherin expression and suppressing the nuclear translocation of β-catenin. In addition, the expression and TGF-β-mediated induction of parathyroid hormone-related protein (PTHrP), one of key osteolytic factors, was blocked in RUNX3-knockdown OSCC cells. Furthermore, treating human osteoblastic cells with conditioned medium derived from RUNX3-knockdown OSCC cells reduced the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin ratio compared with treatment with conditioned medium from RUNX3-expressing cells. These findings indicate that RUNX3 expression in OSCC cells contributes to their bone invasion and the resulting osteolysis by inducing their malignant behaviors and production of osteolytic factors. RUNX3 alone or in combination with TGF-β and PTHrP may be a useful predictive biomarker and therapeutic target for bone invasion by oral cancer.

AB - High recurrence and lower survival rates in patients with oral squamous cell carcinoma (OSCC) are associated with its bone invasion. We identified the oncogenic role of RUNX3 during bone invasion by OSCC. Tumor growth and the generation of osteolytic lesions were significantly inhibited in mice that were subcutaneously inoculated with RUNX3-knockdown human OSCC cells. RUNX3 knockdown enhanced TGF-β-induced growth arrest and inhibited OSCC cell migration and invasion in the absence or presence of transforming growth factor-β (TGF-β), a major growth factor abundant in the bone microenvironment. RUNX3 knockdown induced cell cycle arrest at the G1 and G2 phases and promoted G2 arrest by TGF-β in Ca9.22 OSCC cells. RUNX3 knockdown also inhibited both the basal and TGF-β-induced epithelial-tomesenchymal transition by increasing E-cadherin expression and suppressing the nuclear translocation of β-catenin. In addition, the expression and TGF-β-mediated induction of parathyroid hormone-related protein (PTHrP), one of key osteolytic factors, was blocked in RUNX3-knockdown OSCC cells. Furthermore, treating human osteoblastic cells with conditioned medium derived from RUNX3-knockdown OSCC cells reduced the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin ratio compared with treatment with conditioned medium from RUNX3-expressing cells. These findings indicate that RUNX3 expression in OSCC cells contributes to their bone invasion and the resulting osteolysis by inducing their malignant behaviors and production of osteolytic factors. RUNX3 alone or in combination with TGF-β and PTHrP may be a useful predictive biomarker and therapeutic target for bone invasion by oral cancer.

UR - http://www.scopus.com/inward/record.url?scp=85012023624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012023624&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14071

DO - 10.18632/oncotarget.14071

M3 - Article

VL - 8

SP - 9079

EP - 9092

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 6

ER -